RBC Capital analyst Brian Abrahams is nudging his price target on Intercept down to $134 from $135 on adjustment of his model to a blend of DCF and probability-adjusted multiple but also keeping his Outperform rating on the stock after its Q3 results and raised FY19 Ocavia sales guidance. The analyst is positive on the company's "substantial progress establishing the commercial infrastructure and payer network ahead of the OCA launch in NASH" and believes that the stock is a multi-billion dollar out-year opportunity that is currently underappreciated by investors.